The Myc proto-oncogene contributes to the pathogenesis of more than 50 percent of human cancers including prostate cancers. Malignant transformation by Myc is known to transcriptionally upregulate the core pre-mRNA splicing machinery and cause mis-regulation of alternative splicing. However, our understanding of how changes of splice isoforms affect the cancer phenotype is limited and how these changes are directed by Myc remains largely unknown. Here, we performed a signaling pathway-guided differential splicing analysis to identify Myc dependent splicing events, including an HRAS cassette exon that is repressed by Myc transformation across multiple tumor types. To molecularly dissect the regulation of this HRAS cassette exon, we used anti...
Alternative splicing (AS) is a co- or post-transcriptional process by which one gene gives rise to m...
Background: Dysregulation of splicing variants (SVs) expression has recently emerged as a novel canc...
Aberrant profiles of pre-mRNA splicing are frequently observed in cancer. At the molecular level, an...
The Myc proto-oncogene contributes to the pathogenesis of more than 50 percent of human cancers incl...
The MYC proto-oncogene contributes to the pathogenesis of more than half of human cancers. Malignant...
We sought to define the landscape of alternative pre-mRNA splicing in prostate cancers and the relat...
Alterations in RNA splicing are frequent in human tumors. Two recent studies of lymphoma and breast ...
High spliceosome activity is a dependency for cancer cells, making them more vulnerable to perturbat...
Cancer cells are differentially dependent on the splicing machinery compared to normal untransformed...
The splicing factor Sam68 is upregulated in many human cancers, including prostate cancer (PCa) wher...
Since early in evolutionary history, alternative RNA splicing has been an important method for metaz...
Mutations causing aberrant splicing are frequently implicated in human diseases including cancer. He...
Dysregulation of splicing variants (SVs) expression has recently emerged as a novel cancer hallmark....
Alternative splicing (AS) is a co- or post-transcriptional process by which one gene gives rise to m...
Background: Dysregulation of splicing variants (SVs) expression has recently emerged as a novel canc...
Aberrant profiles of pre-mRNA splicing are frequently observed in cancer. At the molecular level, an...
The Myc proto-oncogene contributes to the pathogenesis of more than 50 percent of human cancers incl...
The MYC proto-oncogene contributes to the pathogenesis of more than half of human cancers. Malignant...
We sought to define the landscape of alternative pre-mRNA splicing in prostate cancers and the relat...
Alterations in RNA splicing are frequent in human tumors. Two recent studies of lymphoma and breast ...
High spliceosome activity is a dependency for cancer cells, making them more vulnerable to perturbat...
Cancer cells are differentially dependent on the splicing machinery compared to normal untransformed...
The splicing factor Sam68 is upregulated in many human cancers, including prostate cancer (PCa) wher...
Since early in evolutionary history, alternative RNA splicing has been an important method for metaz...
Mutations causing aberrant splicing are frequently implicated in human diseases including cancer. He...
Dysregulation of splicing variants (SVs) expression has recently emerged as a novel cancer hallmark....
Alternative splicing (AS) is a co- or post-transcriptional process by which one gene gives rise to m...
Background: Dysregulation of splicing variants (SVs) expression has recently emerged as a novel canc...
Aberrant profiles of pre-mRNA splicing are frequently observed in cancer. At the molecular level, an...